|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Massachusetts Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MassachusettsLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Ariad Pharmaceuticals, Inc.
| | | Phone: | (617) 494-0400 | Fax: | (617) 494-8144 | Year Established: | 1991 | Ticker: | ARIA | Exchange: | NASDAQ | Main Contact: | Paris Panayiotopoulos, President & CEO | | Other Contacts: | Jennifer L. Herron, Senior VP & CCO Manmeet S. Soni, Executive VP & CFO lona Kogan, Esq., Senior VP & General Counsel Hugh M. Cole, Senior VP & CBO Timothy P. Clackson, Ph.D., President R&D & CSO Daniel M. Bollag, Ph.D., Senior VP, Regulatory Affairs and Quality
| | Company Description | ARIAD is an emerging global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. ARIAD’s approach to structure-based drug design has led to several internally discovered, molecularly targeted product candidates for drug-resistant or difficult-to-treat cancers, including chronic myeloid leukemia and certain forms of non-small cell lung cancer.
On Jan. 9, 2017, ARIAD announced an agreement to be acquired by Takeda Pharmaceutical Company Limited under which Takeda will acquire all of the outstanding shares in ARIAD for $24.00 per share in cash, or a total enterprise value of approximately $5.2 billion. | |
|
|
|
|
|